Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsThe FDA has approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. It's only the second weekly basal insulin to earn FDA approval, following Novo Nordisk's Awiqli in March. Onswik could slash the number of injections by more than 300 per year compared to daily insulin regimens.
The FDA has approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin designed to help adults with type 2 diabetes maintain steady blood sugar levels for a full seven days. Approved for use alongside diet and exercise, Onswik becomes only the second once-weekly basal insulin cleared by the FDA — following Novo Nordisk's Awiqli, which was approved in March 2026.
Approval was based on data from four phase 3 QWINT trials enrolling more than 3,400 adults with type 2 diabetes. Across all four studies, Onswik demonstrated A1C reductions that were noninferior to daily basal insulins glargine and degludec, with a comparable safety profile. Notably, Onswik is not approved for type 1 diabetes due to an increased risk of severe hypoglycemia.
By the Numbers:
Why it matters: For the millions of people managing type 2 diabetes, the burden of daily injections is a real barrier to adherence. A once-weekly option could meaningfully improve patient experience and treatment consistency.
